required higher concentrations (84.33% at 75% MBC). These results demonstrated that marine bacterial metabolites produce biocompatible Se-Cu BMNPs with potent antioxidant, anti-inflammatory, antimicrobial, and antibiofilm properties suitable for biomedical applications.
Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.
monoamine oxidase B inhibitorsParkinson's diseaseblood-brain barrier permeabilityADME prediction
Toxicology Mechanisms and Methods · مجلد 36 (3) · 412-431
Methotrexate (METX) is a widely used chemotherapeutic and immunosuppressive agent, frequently employed as a first-line treatment for various malignancies and autoimmune disorders. Despite its clinical efficacy, METX is known to induce cardiotoxicity primarily through mechanisms involving oxidative stress, inflammation, and apoptosis. Apigenin (API), a natural dietary flavonoid, exhibits potent antioxidant and anti-inflammatory properties. The current study evaluated the protective effects of API against METX-induced cardiotoxicity in mice, focusing on the modulation of transforming growth factor-β (TGF-β)/(SMAD2) signaling. Molecular docking was done to investigate the possible inhibition of TGF-β by API and bioinformatic tools were utilized to investigate the correlation between the target proteins. Male Swiss albino mice were randomly distributed to four groups: Group I: a saline group, Group II: a METX control group (20 mg/kg, per week), Group III: METX + API (40 mg/kg, per day) and Group IV: METX + API (80 mg/kg, per day, via oral gavage); the study continued for three weeks. Our findings suggest that API administration significantly mitigated METX cardiotoxicity and serum CK-MB, likely through attenuation of the inflammatory cytokines (NF-κB, IL-1β, TNF-α, and IL-6) and suppression of cardiac TGF-β/SMAD2 signaling. The congruence between bioinformatics and experimental validation findings strongly highlighted API as a promising therapeutic candidate for alleviating METX cardiotoxicity. While the current data reveals key underlying molecular mechanisms for API′s cardioprotective effect, further comprehensive studies across diverse cardiotoxicity models are essential to fully elucidate cardioprotective effect of API.
Frontiers in Pharmacology · مجلد 17 · 1871321-1871321
Background Although microRNAs have been investigated, the reno-protective role of microRNA-205 (miR-205) in cyclophosphamide (CPA)-induced nephrotoxicity has not yet been explored. Therefore, this study evaluated the influence of buspirone on miR-205 and its downstream target EGLN2, focusing on oxidative and ER stress as key drivers of renal injury. This represents a significant gap in nephrotoxicology and epigenetic Toxicology research. Methods Animals were randomly allocated among four groups (n = 8), including the normal control group and the CPA group that received one intraperitoneal injection of CPA at 200 mg/kg on day 7. Buspirone at 5 or 10 mg/kg per day was administered by oral gavage for ten consecutive days, whereas CPA injected on the seventh day. At experimental completion, blood samples and renal tissues were subjected to analysis using biochemical, histopathological, immunohistochemical, Western blotting, and qRT-PCR techniques. Results CPA induced marked renal dysfunction, reflected by elevated SCr, BUN, NGAL, and KIM-1, with evident histopathological damage. This was accompanied by miR-205 suppression, EGLN2 upregulation, impaired Nrf2 signaling, increased PC levels, and stimulation of PERK/eIF2α/ATF4/CHOP-linked ER stress signaling ( p < 0.01). Concurrently, activation of JNK1, Fos, and NF-κB increased inflammatory cytokines, and initiated caspase-dependent apoptotic signaling ( p < 0.01). Buspirone pretreatment mitigated these alterations, accompanied by increased miR-205 expression, reduced EGLN2 expression, enhanced Nrf2-associated antioxidant defenses, and attenuation of ER stress, inflammation, and apoptosis, thereby preserving renal function and tissue integrity. Conclusion These findings highlight the preventive renoprotective potential of buspirone against CPA-induced nephrotoxicity and underscore the relevance of miR-205/EGLN2 signaling in renal stress responses. Future toxicokinetic and toxicodynamic studies should evaluate buspirone’s safety in tumor treatment.
Introduction: Neurodegenerative diseases present major challenges in biomedical research, and identifying natural sources with potential cytoprotective effects remains an important exploratory goal. This study investigates the cytoprotective properties of Fagonia arabica in human neuroblastoma (SK‑N‑SH) cells exposed to oxidative and neurotoxic stressors. Methods: he dried plant material was subjected to a sequential solvent extraction method. The antioxidant and anti-inflammatory activity was assessed by standard procedures. Cytotoxicity was assessed in L929 fibroblasts, and in vitro neuroprotective effects were examined in SK‑N‑SH neuroblastoma cells exposed to trimethyltin (TMT). The GCMS analysis identified the phytocompounds, and an in silico study was performed using molecular docking against targeted proteins. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Discussion: The biological activities of the extract are likely due to its phytochemical constituents, particularly flavonoids and phenolic compounds. The in silico predictions supported the experimental findings of anti-inflammatory and antioxidant activities. The extract also showed low cytotoxicity and demonstrated cytoprotective effects under oxidative stress conditions, suggesting potential therapeutic value, warranting further investigation into its mechanisms and pharmacological applications. Conclusion: Fagonia arabica demonstrated antioxidant, anti-inflammatory, and preliminary neuroprotective effects at the cellular level. While these findings support the plant’s potential as a source of bioactive compounds with neuroprotective potential, the study does not directly model the complex pathology of Alzheimer’s disease. Further investigations using disease-relevant models are required to clarify its therapeutic relevance
Frontiers in Aging Neuroscience · مجلد 18 · 1742343-1742343
Background: Sleep is a fundamental biological process essential for maintaining mental, emotional, and physical health. Chronic sleep deprivation (SD), particularly in aging, is associated with oxidative stress, neuroinflammation, apoptosis, and cognitive and behavioral impairments. Oxytocin, a hypothalamic neuropeptide with reported antioxidant and anti-inflammatory properties, may modulate stress-related pathways; however, its role in mitigating SD-induced brain alterations remains unclear. This study investigated whether peripheral oxytocin administration influences brain and behavioral changes induced by chronic SD in aged rats. Methods: Male Sprague Dawley rats aged 20-24 months were divided into four groups: control, oxytocin-treated, SD, and SD with oxytocin treatment. Chronic SD was induced using a modified multiple platform method. Behavioral assessments were conducted to evaluate locomotor and exploratory activity. Serum cortisol was measured as a systemic stress marker, while brain tissues were analyzed for oxidative stress and inflammatory markers. Gene expression of Psen1 and Htr2a, oxytocin receptor protein levels, and histopathological changes, including gliosis and apoptosis, were also evaluated. Results: Chronic SD resulted in significant impairments in locomotor and exploratory behaviors, elevated serum cortisol levels, and increased oxidative stress and inflammatory markers. SD also altered the expression of Psen1 and Htr2a, reduced oxytocin receptor protein levels, and was associated with histological evidence of gliosis and apoptosis in brain tissues. Peripheral oxytocin administration attenuated many of these SD-induced alterations. However, because oxytocin was administered peripherally and central oxytocin levels or receptor engagement were not directly assessed, the findings cannot be interpreted as definitive evidence of direct central neuroprotection. Conclusion: The results suggest that oxytocin modulates stress responses, oxidative balance, and inflammatory pathways in aged rats subjected to chronic sleep deprivation. Although the precise central mechanisms remain unresolved, these findings support a potential role for oxytocin in mitigating SD-associated pathophysiological changes in aging and warrant further mechanistic studies to clarify its neuroprotective potential.